Catalyst
Slingshot members are tracking this event:
European Commission Expected to Make Final Decision in ~60 Days on Gilead's (GILD) Vemlidy in Adults with Chronic HBV Infection
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2017
Occurred Source:
http://www.gilead.com/news/press-releases/2017/1/european-commission-grants-marketing-authorization-for-gileads-vemlidy-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b-virus-infection
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
European Comission, Chmp, Vemlidy, Chronic Hepatits B Virus Infection, Hbv, Tenofovir Alafenamide
